The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Nanoparticle‐Mediated Delivery of Inhaled Immunotherapeutics for Treating Lung Metastasis
Abstract
Despite the critical breakthrough achieved by immune checkpoint blockade (ICB), the clinical benefits are usually restricted by inefficient infiltration of immune cells and immune‐associated adverse effects. Noninvasive aerosol inhalation, as a definitive procedure for treatment of respiratory diseases, for ICB immunotherapy against lung metastasis, has not been realized to the best knowledge. Herein, an inhaled immunotherapeutic chitosan (CS)–antibody complex is developed for immunotherapy against lung cancer. In this system, CS is used as a carrier to assemble with anti‐programmed cell death protein ligand 1 (aPD‐L1) to enable efficient transmucosal delivery. Moreover, CS exhibits adjuvant effects to drive potent immune responses via activating the cyclic‐di‐GMP‐AMP synthase (cGAS)‐stimulator of interferon genes (STING) pathway. Interestingly, repeated inhalation of CS/aPD‐L1 complex can effectively activate the immune system by promoting the infiltration of different immune cells especially CD8+ T cells around tumor lesions, and finally prolongs the survival of mice to 60 days. Thus, the work presents a unique aerosol inhalation delivery system for ICB antibody, which is promising for immunotherapy against lung metastasis without the concern of systemic toxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., Thomas, C. A., Barlesi, F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716948 · Cited by 3,733
STING: infection, inflammation and cancer.
Barber, G. N. (2015) · Nature Reviews Immunology · doi:10.1038/nri3921 · Cited by 1,313
Fuertes, M. B., Kacha, A. K., Kline, J., Woo, S.-R., Kranz, D. M., Murphy, K. M., & Gajewski, T. F. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101159 · Cited by 1,192
Type I interferon is selectively required by dendritic cells for immune rejection of tumors
Diamond, M. S., Kinder, M., Matsushita, H., Mashayekhi, M., Dunn, G. P., Archambault, J. M., Lee, H., Arthur, C. D., White, J. M., Kalinke, U., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101158 · Cited by 1,081
Chiba, S., Baghdadi, M., Akiba, H., Yoshiyama, H., Kinoshita, I., Dosaka-Akita, H., Fujioka, Y., Ohba, Y., Gorman, J. V., Colgan, J. D., et al. (2012) · Nature Immunology · doi:10.1038/ni.2376 · Cited by 838
Nanotechnology for protein delivery: Overview and perspectives
Yu, M., Wu, J., Shi, J., & Farokhzad, O. C. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.10.012 · Cited by 410
Cited by
Chemical and Biomolecular Strategies for STING Pathway Activation in Cancer Immunotherapy
Garland, K. M., Sheehy, T. L., & Wilson, J. T. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00750 · Cited by 357
Yee Kuen, C., & Masarudin, M. J. (2022) · Molecules · doi:10.3390/molecules27020473 · Cited by 78
Metadata
- Authors
- Jin, Q., Zhu, W., Zhu, J., Zhu, J., Shen, J., Liu, Z., Yang, Y., & Chen, Q.
- Venue
- Advanced Materials
- Publisher
- Wiley
- Published
- 2021-01-14
- Volume
- 33
- Issue
- 7
- Pages
- e2007557-e2007557
- ISSN
- 0935-9648 (ISSN-L)
- 1521-4095
- OpenAlex
- W3120903220
- Cited by
- 169
- References
- 6
- FWCI
- 17.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Nanoparticle‐Mediated Delivery of Inhaled Immunotherapeutics for Treating Lung Metastasis. https://app.cochat.ai/papers/10.1002/adma.202007557
- The paper
- Jin, Q., Zhu, W., Zhu, J., Zhu, J., Shen, J., Liu, Z., Yang, Y., & Chen, Q. (2021). Nanoparticle‐Mediated Delivery of Inhaled Immunotherapeutics for Treating Lung Metastasis. Advanced Materials. https://doi.org/10.1002/adma.202007557
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.